A prognostic score for prostatic adenocarcinoma based on clinical, histological, biochemical and cytometric data from the primary tumour

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 2095-2100

  Lipponen, P ^a   Vesalainen, S ^a   Kasurinen, J ^a   Ala Opas, M ^a   Syrjanen K ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Apoptosis; Flow cytometry; Grade; Morphometry; Progression; Prostatic adenocarcinoma; Survival; Tumour infiltrating lymphocyte

Indexed keywords

ACID PHOSPHATASE;

ACID PHOSPHATASE BLOOD LEVEL; ADULT; AGE; AGED; APOPTOSIS; ARTICLE; BIOCHEMISTRY; CANCER SURVIVAL; CELL NUCLEUS; CLINICAL EXAMINATION; COHORT ANALYSIS; CYTOMETRY; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; TUMOR ASSOCIATED LEUKOCYTE;

ADENOCARCINOMA; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; APOPTOSIS; CELL CYCLE; COHORT STUDIES; CREATININE; DNA, NEOPLASM; ENZYME TESTS; FOLLOW-UP STUDIES; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; MITOTIC INDEX; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PLOIDIES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0029759693     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Muir CS, Nectoux J, Staszewski J: The epidemiology of prostatic cancer. Acta Oncol 30: 133-140, 1991.
2. International Union against Cancer (UICC): TNM classification of malignant tumours, ed 3, Geneva, UICC, 1978.
3. Gleason DF: Histologic grading and clinical staging of prostatic carcinoma. In: Urologic pathology: The prostate. Edited by M. Tannenbaum. Philadelphia: Lea & Febiger, 1977. p. 171.
4. Mostofi FK: Grading of prostatic carcinoma. Cancer Chemother Rep 59: 111-117, 1975.
5. Gaeta JF, Asirwatham JE, Miller G, Murphy GP: Histologic grading of primary prostatic cancer;a new approach to an old problem. J Urol 123: 689-693, 1980.
6. Visakorpi T, Kallioniemi O-P, Paronen IYI, Isola JJ, Heikkinen AI, Koivula TA: Flow cytometric analysis of DNA ploidy and S phase fraction from prostatic carcinomas: implications for prognosis and response to endocrine therapy. Br J Cancer 64: 578-582, 1991.
7. Song J, Cheng WS, Cupps RE, Earle JD, Farrow GM, Lieber MM: Nuclear Deoxyribonucleic acid content measured by static cytometry: important prognostic association for patients with clinically localized prostate carcinoma treated by external beam radiotherapy. J Urol 147: 794-797, 1992.
8. Vesalainen S, Nordling S, Lipponen P, Talja M, Syrjänen K: Progression and survival in prostatic adenocarcinoma. A comparison of DNA ploidy and S phase fraction. Br J Cancer 70: 309-314, 1994.
9. Vesalainen S, Lipponen P, Talja M, Syrjänen K: Nuclear morphomretry has prognostic value only in TIM0 prostatic adenocarcinoma. The Prostate 1995, in press.
10. Epstein JI, Berry SJ, Eggleston JC: Nuclear roundness factor. A predictor of progression in untreated stage A2 prostate cancer. Cancer 54: 1666-1671, 1984.
11. Aaltomaa S, Lipponen P, Eskelinen M, Kosma V-M, Marin S, Alhava E. Syrjänen K: Prognostic score combining clinical, histological and morphometric variables in assessment of the disease outcome in female breast cancer. Int J Cancer 49: 885-892, 1991.
12. Vesalainen S, Lipponen P, Talja M, Syrjänen K: Mitotic indices as prognostic factors in prostatic adenocarcinoma. The Prostate 26: 80-86, 1995.
13. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS. Oestcrling JE: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 11: 2158-2166, 1993.
14. Pontes JE: Biological markers in prostate cancer. J Urol 130: 1037-1047, 1983.
15. Desoize B, Amico S, Larbe H, Coninx P, Jardillier J-C: Phosphatase isoenzymes as bone metastasis markers in prostatic carcinoma. Clin Biochem 24: 443-446, 1991.
16. Merrick MV, Ding CL, Chisholm GD, Elton RA: Prognostic significance of alkaline and acid phosphatase and skeletal scintigraphy in carcinoma of the prostate. Br J Urol 57: 715-720, 1985.
17. Walsh PC, Gittes RF, Perlmutter AD, Stamey TA: Campbell's Urology, fifth edition, vol. 2, pp. 1463-1518.
18. Black MM, Kerpe S, Speer FD: Survival in breast cancer cases in relation to the structure of the primary tumour and the regional lymph nodes. Surg Gynecol Obstet 100: 543-547, 1995.
19. Walker NI, Harmon BV, Gobe GC, Kerr JFR: Patterns of cell death. Meth Achiev. exp. Pathol 13: 18-54, 1988.
20. Lipponen PK, Eskelinen MJ, Jauhiainen K, Harju E, Terho R: Tumour infiltrating lymphocytes as an independent prognostic factor in transitional cell bladder cancer. Eur J Cancer 29A: 69-75, 1993.
21. Aaltomaa S, Lipponen PK, Eskelinen MJ, Kosma V-M, Marin S, Alhava E, Syrjänen K: Lymphocyte infiltrates as a prognostic variable in female breast cancer. Eur J Cancer 28: 859-864, 1992.
22. Fernlund P, Hanson A, Laurell C-B, Lundh B: Klinisk kemi i praktisk medicin. Lund: Studentlitteratur, 1986.
23. Lee E, Desu M: A computer program for comparing k samples with right censored data. Comput Prog in Biomed 2: 315-320, 1972.
24. Cox DR: Regression models and life tables with discussion. J R Stat Soc B 34: 187-220, 1972.
25. Vesalainen S, Lipponen P, Talja M, Syrjänen K: Histological prognostic factors in prostatic adenocarcinoma. Eur J Cancer 30A: 1797-1803, 1995.
26. Collan Y, Eskelinen M, Lipponen P, Nordling S, Pesonen E, Pajarinen P, Kettunen K, Alhava E: Improving the accuracy of prognosis of breast cancer. Multivariate combination of nodal status, proliferation index, tumor size and DNA ploidy in prognostication. Acta Oncol 1994, in press.
27. Lipponen PK, Eskelinen MJ, Kiviranta J, Pesonen E: Prognosis of transitional cell bladder cancer: a multivariate prognostic score for improved prediction. J Urol 146: 1535-1540, 1991.